Drug Profile
Yogliptin - Easton Biopharmaceuticals
Latest Information Update: 13 Apr 2022
Price :
$50
*
At a glance
- Originator Easton Biopharmaceuticals
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 01 Jan 2022 Phase-III clinical trials in Type 2 diabetes mellitus (In adults, In the elderly) in China (PO) (NCT05318326)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in China (PO, Tablet)
- 18 Oct 2018 Easton Biopharmaceuticals initiates enrolment in a phase I trial in healthy volunteers in China (ChiCTR1800018877)